Peptide Research Glossary: Key Terms Explained in Plain English

What do the key terms in peptide research mean?

This glossary defines the core terms used in peptide research literature. Understanding these terms is a prerequisite for reading studies critically. Knowing what a word means in context — surrogate endpoint vs. clinical endpoint, in vitro vs. in vivo, FDA approval vs. compounding listing — prevents a reader from overinterpreting what a study actually showed. The entries below aim for scientific accuracy without unnecessary jargon.

How to use this glossary

Research terms are not interchangeable labels for “good evidence.” They describe different parts of a question: what was measured, where it was measured, how participants were assigned, and how confidently a result can be interpreted. A paper can use sophisticated molecular language while still answering only a narrow question. For a practical reading sequence, see how to read peptide research.

Context also matters when a familiar name appears in a paper. BPC-157 is one example of a peptide discussed across preclinical literature; its name alone does not identify a proven human outcome. Likewise, a result in a cell culture is not the same kind of evidence as a result in people. The glossary uses those distinctions rather than treating “research” as one uniform category.

Peptide research glossary

Adverse event

Any unfavorable sign, symptom, or disease temporally associated with a medical intervention. The term does not imply causation: an event may have another explanation. Researchers distinguish an adverse event from a side effect, which generally describes an effect considered related to a drug.

Agonist

A molecule that binds a receptor and activates it, producing a biological response. The size and character of that response can depend on the receptor, the tissue, the concentration, and the signaling system involved.

Amino acid

The structural unit of peptides and proteins. Peptides are chains of amino acids linked by peptide bonds, and the order and chemical properties of those units help determine how a chain folds, binds, and behaves.

Analog

A compound with structural similarity to a reference molecule but with deliberate modifications. Those changes may alter potency, selectivity, stability, metabolism, or pharmacokinetics, so evidence about the reference molecule cannot automatically be transferred to the analog.

Antagonist

A molecule that binds a receptor but does not activate it. By occupying the receptor, it can block or reduce the activity of an agonist, although the observed effect depends on binding strength, concentration, and biological context.

Bioavailability

The fraction of an administered dose that reaches the systemic circulation in active form. Route of administration affects bioavailability, as can absorption, degradation, formulation, and first-pass metabolism. A measured concentration is not by itself proof of benefit.

Biomarker

A measurable biological indicator, such as a blood concentration, laboratory value, or imaging feature. A biomarker change can help describe mechanism or risk, but it does not automatically confirm a clinical benefit that patients would notice.

Blinding

A study design feature that keeps participants, investigators, outcome assessors, or some combination unaware of group assignment. Blinding can reduce bias caused by expectations, differential care, or interpretation of subjective outcomes.

Clinical significance

Whether an observed effect is large enough to matter to patients or clinical practice. It is distinct from statistical significance, which concerns how compatible a result is with chance under a specified statistical model.

Compounding

The preparation of a drug product from bulk ingredients by a licensed pharmacy for a specific patient or circumstance. Compounded drugs are not FDA approved as individual products; a compounding listing is not the same as approval. Learn what FDA approval covers.

Confidence interval

A range of values estimated to contain the true effect size with a specified probability under a statistical procedure. Wider intervals indicate more uncertainty, while an interval crossing a relevant null value may make the direction or practical size of an effect less certain.

Endogenous

Produced naturally within an organism. For peptides, endogenous means internally produced, in contrast with exogenous, which means supplied from outside. Measuring an endogenous concentration does not answer the same question as administering a peptide.

Endpoint

The outcome measured in a study. Primary endpoints are defined before data collection and usually carry the central interpretive weight. Surrogate endpoints are biological proxies for clinical outcomes and require careful validation before they can stand in for patient benefit.

Exogenous

Derived from or administered from outside an organism. Exogenous peptide administration is distinct from measuring endogenous concentrations, because an intervention changes the exposure question and may introduce different pharmacokinetic and safety considerations.

FDA approval

A regulatory conclusion that a defined drug product, for a defined indication, manufactured by a specific sponsor, has met safety and efficacy requirements in a reviewed application.1 Approval is not transferable to related molecules, formulations, manufacturers, or different uses. This article explains the distinction in more detail.

Fragment

A portion of a larger peptide or protein sequence. A fragment may differ substantially in activity, stability, and pharmacokinetics from the full-length molecule. TB-500 is a fragment of full-length thymosin beta-4 (Tβ4); evidence for full-length Tβ4 does not automatically transfer to the fragment.

GHRH (growth hormone-releasing hormone)

A hypothalamic peptide that stimulates pituitary cells to release growth hormone. Some synthetic peptides mimic GHRH signaling. Research discussions should distinguish receptor biology, measured hormone changes, and clinical outcomes; these are related but not equivalent claims. Read more about growth hormone peptides.

Ghrelin receptor / GHS-R1a (growth hormone secretagogue receptor 1a)

The receptor activated by ghrelin and by growth hormone secretagogues such as ipamorelin. It is expressed in the pituitary and other tissues. A receptor name identifies a biological target, not a conclusion about the safety or effectiveness of every molecule that interacts with it.

Half-life

The time required for the concentration of a substance in the body to decrease by half. Half-life helps researchers describe persistence and determines dosing interval in pharmacology, but it does not by itself establish efficacy, safety, or the appropriate use of a product.

IGF-1 (insulin-like growth factor 1)

A hormone produced primarily in the liver in response to growth hormone. It is often measured as a surrogate marker in growth hormone research, but a concentration change does not directly equal a clinical outcome.

In vitro

Latin for “in glass.” In vitro experiments are conducted in cells or tissue cultures outside a living organism. They are useful for investigating mechanism under controlled conditions, but they cannot reproduce whole-body biology, exposure, metabolism, or every interaction among organs.

In vivo

Latin for “within the living.” In vivo experiments are conducted in a living organism, including an animal model. They add systemic biology, but the model species, dose, disease state, and conditions affect how confidently findings can be generalized to humans. Compare human and animal peptide research.

Mechanism of action

The specific biochemical process by which a compound produces its effect, such as receptor binding and downstream signaling. Knowing a mechanism helps generate hypotheses, but it does not establish that the predicted effect will occur in humans or improve a clinical outcome.

Meta-analysis

A statistical method that combines results from multiple studies to estimate an overall effect. Its quality depends on the studies included, their risk of bias, the consistency of their methods, and whether the statistical combination is scientifically appropriate.

Mitochondrial signaling

Communication pathways that originate in or are regulated by mitochondria. It is relevant to peptides such as MOTS-c, which is encoded in mitochondrial DNA. Findings about a pathway describe biology; they do not alone establish a human therapeutic effect.2

NAD+ (nicotinamide adenine dinucleotide)

A coenzyme essential to cellular energy metabolism and redox reactions. NAD+ levels decline with age in animal models; its role in human aging is an active research area. NAD+ is not a peptide, but it is frequently discussed alongside peptide stacks.

Observational study

Research that measures or follows participants without assigning an intervention. Observational studies can identify associations and generate hypotheses, but differences between groups may explain a finding, so they cannot establish causation with the same strength as a randomized trial.

Peptide

A chain of amino acids linked by peptide bonds, typically shorter than a protein. Length, sequence, chemical modifications, and three-dimensional structure all influence biological activity. A name shared by two products does not necessarily mean they are identical molecules.

Pharmacodynamics

The study of what a drug does to the body. It includes receptor binding, signaling, physiological responses, and downstream effects. Pharmacodynamic evidence can clarify biological action without proving that an outcome is clinically meaningful.

Pharmacokinetics

The study of what the body does to a drug: absorption, distribution, metabolism, and elimination. Pharmacokinetics describes exposure over time and helps interpret why results may differ between routes, populations, formulations, or species.

Placebo

An inert control treatment that matches the active treatment in appearance and study experience as closely as possible. In trials, a placebo helps separate a pharmacological effect from expectation, natural change, and other effects of participating in research.

Preclinical

Research conducted before human trials, typically in cells or animals. Preclinical work generates hypotheses and safety signals for later study; it is not direct evidence of human efficacy. The species, model, and outcome determine what question it actually addresses.

Protein

A long chain of amino acids with a defined three-dimensional structure. Peptides are generally shorter and may fold differently, although the boundary between peptide and protein is not defined by one universal length cutoff in every field.

Randomized controlled trial (RCT)

A study design in which participants are randomly assigned to intervention or control groups. Randomization helps balance known and unknown factors between groups, making an RCT a high-evidence design for testing causal claims when conducted and reported well.

Receptor

A protein structure on or in a cell that binds a specific molecule and initiates, changes, or blocks a biological response. Receptor binding is one step in a pathway, not a guarantee of a desired effect in a whole organism.

Statistical significance

A threshold, commonly p < 0.05, indicating that an observed result is unlikely to be due to chance alone under a stated model. It does not indicate the size, reliability across studies, or clinical importance of an effect.

Surrogate endpoint

A biological measurement used as a proxy for a clinical outcome. A surrogate endpoint result does not automatically mean a clinical benefit will follow; the relationship must be supported by evidence linking the surrogate to outcomes that matter to patients.

Systematic review

A structured literature search and synthesis following a defined protocol. It aims to find relevant studies transparently and assess their limitations, combining evidence more rigorously than a narrative review when the methods are appropriately designed and reported.

Frequently asked questions

What is the difference between a peptide and a protein?

Both are chains of amino acids joined by peptide bonds. Peptides are generally shorter, while proteins are longer and typically adopt more elaborate three-dimensional structures, but biology uses no single length boundary that resolves every case.

What is the difference between statistical significance and clinical significance?

Statistical significance addresses how compatible an observed result is with chance under a model. Clinical significance asks whether the size of that result matters to patients or practice. A tiny effect can be statistically significant in a large study.

Why does in vitro or animal evidence not directly translate to human outcomes?

Cells and animals provide useful biological information, but humans differ in physiology, metabolism, exposure, disease context, and outcomes that matter. Translation therefore requires appropriately designed human studies rather than an assumption that mechanism guarantees benefit.

What does FDA approval actually cover?

FDA approval covers a defined drug product, formulation, manufacturing process, sponsor, and indication reviewed in an application. It does not automatically cover a related molecule, a different formulation, a compounded product, or an unreviewed use.

Why do glossary definitions matter when reading peptide research?

Definitions reveal what a study actually tested. Distinguishing an endpoint from a surrogate, an association from causation, and endogenous measurement from exogenous administration prevents broad claims from being built on narrower evidence.